Clinical trials: Renal Transplantation
Renal Transplantation, Heart Transplantation
Intracellular and Renal/Myocardial Tissue Concentrations of Cyclosporine A (CsA) and Rejection Frequency Following Transplantation
The primary objective is to investigate intralymphocyte concentrations of CsA in renal and heart transplant recipients to elucidate the association between the intracellular concentration and efficacy (rejection episodes and…
- Trial name
- NCT00139009
- Testing
- Cyclosporine A
- Where
- Norway
- Volunteers
- 30 people
- Sponsor
- University of Oslo School of Pharmacy
Transplantation Infection, Cytomegalovirus Infection
Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A
Cytomegalovirus (CMV) infection is the most frequent opportunistic viral infection after transplantation. It is associated with an increased incidence of acute rejection and lower graft and patient survivals.
- Trial name
- EVERCMV (NCT02328963)
- Testing
- Everolimus, mycophenolic acid
- Where
- 9 sites in France
- Volunteers
- 186 people
- Sponsor
- University Hospital, Bordeaux
Liver Transplant, Kidney Transplant
A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant
The purpose of this study is to evaluate the impact of Advagraf, prolonged-release, once daily tacrolimus formulation, on long-term graft survival in kidney and liver allograft recipients.
- Trial name
- ADDRESS (NCT02057484)
- Testing
- Tacrolimus
- Where
- 145 sites in Austria, Belarus and 22 more
- Volunteers
- 2,300 people
- Sponsor
- Astellas Pharma Europe Ltd.
Kidney Transplant
Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients
The purpose of this study is to determine if one drug is superior to another with regard to safety and the preservation of renal function after a kidney transplant.
- Trial name
- NCT00137345
- Testing
- sirolimus
- Where
- 82 sites in United States, Argentina and 19 more
- Volunteers
- 500 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Neuromuscular Block, Renal Transplant Donor of Left Kidney
Deep Versus Moderate Muscle Relaxation During Laparoscopic Donor Nephrectomy in Enhancing Postoperative Recovery
Postoperative recovery after live donor nephrectomy (LDN) is largely determined by the consequences of postoperative pain and analgesia consumptions.
- Conditions
- Neuromuscular Block, Renal Transplant Donor of Left Kidney, Renal Transplant Donor of Right Kidney, Surgery
- Trial name
- RELAX (NCT02838134)
- Testing
- Rocuronium, No additional Rocuronium
- Where
- 2 sites in Netherlands
- Volunteers
- 101 people
- Sponsor
- Radboud University Medical Center
Renal Transplanted Recipients, Kidney Function
Renal Function Prediction in Living Donor Transplant Using Baseline Data
This study aims to predict early post-transplant kidney function in living donor kidney transplant recipients using baseline characteristics of donors and recipients.
- Trial name
- NCT06728995
- Where
- South Korea
- Volunteers
- 3,500 people
- Sponsor
- Seoul National University Hospital
Endocrine System Diseases, Thyroid Diseases
Endocrine Changes and Their Correction in Heart and Lung Transplant Recipients and Donors
The aim of this study is to assess the impact of endocrine changes and their correction on survival and organ function in heart and lung transplant recipients.
- Conditions
- Endocrine System Diseases, Thyroid Diseases, Cortisol Deficiency, Diabetes Insipidus
- Trial name
- NCT04351945
- Testing
- Blood test
- Where
- Hungary
- Volunteers
- 100 people
- Sponsor
- Semmelweis University Heart and Vascular Center
COVID, Kidney Transplant; Complications
Maintenance Versus Reduction of Immunosuppression for Renal Transplant Patients Hospitalized With COVID-19 Disease
This will be a randomized trial of maintenance versus reduction in immunosuppression in adult patients (age >18 years old) with functioning renal transplants admitted to hospital with confirmed COVID-19 disease.
- Conditions
- COVID, Kidney Transplant; Complications, Immunosuppression
- Trial name
- NCT04420364
- Testing
- Maintenance or reduction of immunosuppression
- Sponsor
- Brigham and Women's Hospital
End-stage Renal Disease
The Role of Hepcidin as a Biomarker to Predict Successful Renal Transplantation
High hepcidin concentrations indicate that iron is blocked from secretion from the reservoir. Hepcidin may be useful in prediction functional iron utilization in renal failure patients.
- Trial name
- NCT04575077
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Yonsei University
Complication of Transplanted Liver
Genetic Predisposition-Chronic Nephrotoxicity From CI-Liver Transplant Recipients-Potential Correlation-Urinary Biomarkers
The purpose of this study is to determine the relationship between genomic variants of components of the renin-angiotensin system and the development of kidney problems due to Calcineurin-inhibitors post liver transplant.Also the…
- Trial name
- NCT00857844
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- Northwestern University
Renal Transplantation
Initial Dosage Range of Tacrolimus by Genotyping in Chinese Renal Transplantation
Acute rejection (AR) is the main complication after transplantation, which is a severe risk of chronic rejection and implant devitalization.
- Trial name
- PSIDRTG (NCT00935298)
- Testing
- Tacrolimus
- Where
- 5 sites in China
- Volunteers
- 145 people
- Sponsor
- The Second Artillery General Hospital
Hospital Hyperglycemia, Post-transplant Hyperglycemia
Intensive Glycemic Management and Outcomes Following Liver Transplantation
Most people develop high blood sugars following liver transplant that requires treatment with insulin in the hospital, even if they don't have diabetes, due to stress and use of steroid medications.
- Trial name
- NCT01432093
- Testing
- Intensive glycemic management, Conventional management
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- Mayo Clinic
Kidney Transplantation, Kidney Transplant Rejection
Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR
The purpose of this study is to determine if the combination of once-daily tacrolimus extended-release (EnvarsusXR) and Azathioprine is non inferior with respect to the composite outcome of acute rejection, graft and patient…
- Trial name
- SIMPLE (NCT04773392)
- Testing
- Twice-daily Tacrolimus, Once-daily envarsus XR, Induction Immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Southern California
Kidney Diseases, Transplant Failure
Evaluation of APOL1 Gene Variants in Kidney Donors and Their Impact on Long-term Renal Function in Donors and Recipients
Evaluation of the frequency of APOL1 gene variants in kidney donors and the impact of these variants on the long-term renal function of kidney transplant donors and recipients.
- Trial name
- NCT06116721
- Where
- Brazil
- Volunteers
- 2,450 people
- Sponsor
- Hospital do Rim e Hipertensão
Pancreas-Kidney Transplantation
Simultaneous Pancreas-kidney Transplantation With Campath Protocol
The purpose of this study is to determine and compare the efficacy of Campath-1H/Tacrolimus versus ATG/Tacrolimus/MMF therapy in conjunction with initial short-term steroids in Type 1-diabetic patients undergoing simultaneous…
- Trial name
- NCT00316810
- Testing
- Alemtuzumab, Rabbit Anti-Human Thymocyte Globulin
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Dr. Claudia Bösmüller
Kidney Transplantation
Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1
The principal purpose is the study of the regulation of the expression of ephrin-B1 by immunofluorescence in kidney biopsies of patients with Chronic transplant glomerulopathy (CTG) compared to biopsies prior to the CTG, in same…
- Trial name
- GARRE (NCT02147210)
- Testing
- biological analysis
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Toulouse
Cytomegalovirus Infection
Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections
The purpose of this study is to evaluate the efficacy and the tolerance of letermovir as part of dual antiviral therapy (in association with valganciclovir) in renal transplant recipients with CMV DNAemia, requiring…
- Trial name
- LUCY-1 (NCT06334497)
- Testing
- Letermovir, Valganciclovir
- Where
- 5 sites in France
- Volunteers
- 80 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Renal Failure, Tremors
Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)
This study will evaluate and measure symptomatic hand tremor in stable kidney transplant subjects on Prograf or generic tacrolimus maintenance therapy at baseline (pre-conversion) and following conversion to LCP-Tacro.
- Trial name
- STRATO (NCT01438710)
- Testing
- Prograf, LCP-Tacro
- Where
- 10 sites in United States
- Volunteers
- 44 people
- Sponsor
- Veloxis Pharmaceuticals
End Stage Renal Disease
Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant Recipients
Regulatory CD4+CD25+ T cells (Treg) derived from the thymus and/or peripheral tissues have been demonstrated to broadly control T cell reactivity (14).
- Trial name
- TRACT (NCT02145325)
- Testing
- Expanded Tregs
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwestern University
Epstein-Barr Virus Infections
Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft
Epstein Barr virus infects over 90% of human population and persists during lifetime. After infecting B lymphocytes, EBV remains latent in memory B cells.
- Trial name
- REPLY (NCT04989491)
- Testing
- Rituximab, control group
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Strasbourg, France